Augmedix

Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Augmedix reports record Q4 earnings, eyes growth in healthcare tech

Augmedix demonstrated robust performance in Q4 2022 with strong revenue growth and bookings.
The company's strategic focus on product development and expansion into new markets bodes well for future growth.
While facing challenges in expenses and competition, Augmedix's opportunities for growth are significant.
Investors can be optimistic about Augmedix's outlook given its solid financial performance and growth prospects.

Augmedix reports robust Q1 growth, eyes profitability amid rising expenses

Augmedix demonstrated strong revenue growth, customer retention, and cost management in Q1 2023.
While facing challenges such as increasing expenses and cash outflows, the company remains focused on achieving profitability.
With a solid financial position and growth opportunities ahead, Augmedix is poised for continued success in the healthcare technology sector.

Augmedix reports robust Q2 growth, raises revenue guidance for 2023

Augmedix's Q2 performance reflects strong revenue growth, margin expansion, and strategic partnerships driving market positioning. While facing challenges in managing expenses and achieving profitability, the company remains optimistic about its growth trajectory. Augmedix's focus on innovation and capacity expansion positions it well to capitalize on opportunities for sustained revenue growth and market competitiveness.

Augmedix reports strong Q3 earnings, introduces AI app for clinicians

Augmedix demonstrated robust financial growth and operational improvements in Q3 2023, positioning itself for continued success.
The company's innovative product offerings and strategic partnerships underscore its commitment to driving healthcare efficiency.
While facing challenges such as product adoption ramp-up and regulatory compliance, Augmedix remains focused on growth and innovation.

Augmedix reports robust Q4 earnings, eyes growth in healthcare tech

Augmedix's strong financial performance in Q4 2023 reflects revenue growth, improved EBITDA, and strategic cost management, positioning the company for future success.
Diverse product offerings, positive partnerships, and efficient capital deployment are key strengths driving Augmedix's growth trajectory and market competitiveness.
While facing profitability challenges and the need for revenue diversification, Augmedix has significant opportunities in the expanding healthcare technology market and strong market demand for its products.

Augmedix reports robust Q1 growth, eyes AI-first SaaS transition

Augmedix's Q1 performance reflects strong revenue growth and strategic product launches, despite challenges in revenue outlook and increased expenses.
The company's focus on transitioning to an AI-first SaaS model and leveraging partnerships like HCA Healthcare positions it for future growth.
Optimism about clinical adoption and a commitment to reaching cash flow breakeven by 2025 highlight Augmedix's long-term strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will release fourth quarter and full year 2023 results after the market closes on Monday, March 18, 2024. Following the release, management will host a conference call and audio webcast to review results and provide a brief business and outlook update that same day at 1:30 p.m. PT / 4:30 p.m. ET.

Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024

SAN FRANCISCO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that members of its management team will participate in a fireside chat and host investor meetings at the Citizens JMP Technology Conference taking place in San Francisco on March 4, 2024.

Augmedix to Participate in Citizens JMP Technology Conference

NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Augmedix, Inc. (NASDAQ: AUGX) on behalf of the company's shareholders.  The investigation seeks to determine whether Augmedix's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Augmedix, Inc. (NASDAQ: AUGX)

With deep experience in developing operational efficiency and innovation, Levy will be working to aid Augmedix in scaling its products, accelerating product development, and aligning with the needs of large healthcare enterprises With deep experience in developing operational efficiency and innovation, Levy will be working to aid Augmedix in scaling its products, accelerating product development, and aligning with the needs of large healthcare enterprises

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

SAN FRANCISCO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it will participate in the Maxim Group Virtual Healthcare IT Conference on January 24, 2024. Manny Krakaris, Chief Executive Officer, will join a fireside chat with Allen Klee, Equity Research Analyst.

Augmedix Announces Participation in Maxim Group Virtual Healthcare IT Investor Conference

Augmedix Inc. NASDAQ: AUGX is an artificial intelligence (AI) powered ambient medical documentation solutions provider in the medical sector. It utilizes generative AI for documenting medical records and transcribing medical notes and conversations, which are seamlessly integrated into the electronic health record (EHR) system used by healthcare systems, insurers, offices, and practices.

Augmedix is an ambient AI healthcare optimization play

Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix Go Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix Go

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue

The general availability launch of MedLM will further advance Augmedix's ambient medical documentation product performance SAN FRANCISCO , Dec. 13, 2023 /PRNewswire/ -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today that it has been piloting Google Cloud's Med-PaLM 2 and will integrate Google Cloud's newly introduced MedLM technology into its technology stack. This model suite uses the latest AI developments adapted for healthcare use cases and meets Augmedix's stringent requirements around AI safety, compliance, and enterprise scalability.

Augmedix Partners with Google Cloud to Bring Medically-Tuned AI Technology to Ambient Documentation

Provides Incremental Capital to Expand Augmedix's Commercial Team, while Accelerating Development of Product Roadmap to Address New Market Segments Provides Incremental Capital to Expand Augmedix's Commercial Team, while Accelerating Development of Product Roadmap to Address New Market Segments

Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group

Augmedix dropped in price by 20%+ after announcing a 5.5 million share offering of common stock that was later upsized to 6.25 million shares. Despite concerns of dilution, I rate AUGX a Buy for its revenue growth undergirded by a promising future in the AI marketplace. The Company's product eliminates data entry tasks for doctors, allowing them to focus on delivering care to patients.

Buy Augmedix After $25 Million Equity Funding Round

Augmedix (NASDAQ: AUGX ) stock is falling on Thursday after the remote medical documentation and live support company announced details of a public share offering. That offering has the company selling 6.25 million shares of AUGX stock at a price of $4 per share.

Why Is Augmedix (AUGX) Stock Down 27% Today?

SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has priced the previously-announced underwritten public offering of 6,250,000 shares of its common stock, at a public offering price of $4.00 per share. The offering was upsized from 5,500,000 shares of common stock. The gross proceeds to Augmedix from this offering are expected to be $25 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Augmedix. In addition, Augmedix granted the underwriters a 30-day option to purchase an additional 937,500 shares of its common stock. All of the shares to be sold in the proposed offering will be sold by Augmedix. The offering is expected to close on or about November 20, 2023, subject to satisfaction of customary closing conditions.

Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock

SAN FRANCISCO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock. Augmedix intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by Augmedix.

Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock

The consensus price target hints at a 36.7% upside potential for Augmedix, Inc. (AUGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Augmedix, Inc. (AUGX)? Wall Street Analysts Think 36.67%

Augmedix, Inc. (AUGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable

Augmedix, Inc. (AUGX) Q3 2023 Earnings Call Transcript

SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine months ended September 30, 2023.

Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023

SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will report financial results for the third quarter ended September 30, 2023, on Monday, November 6, 2023, after the market closes. Management will host a conference call that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023

Augmedix, Inc. (AUGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Augmedix, Inc. (AUGX) Soars 7.6%: Is Further Upside Left in the Stock?

Ellipsis Health's AI Technology Will Allow Healthcare Providers Using Augmedix to Seamlessly Screen Patients for Symptoms of Anxiety and Depression SAN FRANCISCO , Oct. 5, 2023 /PRNewswire/ -- Ellipsis Health , the market leader in AI-generated vocal biomarker technology for the identification and monitoring of mental health conditions at scale, today announced a plan for a strategic partnership with Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions. The partnership between the parties will mark a significant milestone in healthcare delivery and will allow healthcare providers using Augmedix to incorporate mental health screenings during their clinical encounters, helping to identify issues earlier and triage patients to the appropriate care.

Ellipsis Health and Augmedix to Partner to Bring Automated Mental Health Screenings to Patient Visits

Augmedix's collaboration with HCA Healthcare led to a 100% surge in the stock, showcasing the positive impact of AI in healthcare. The company's technology platform improves patient care by allowing doctors to remotely access real-time medical records and save time on documentation. Augmedix's partnership with HCA Healthcare for testing and launching Augmedix Go indicates the potential for higher revenues and valuation.

Augmedix: Using Generative AI To Document Medical Records

Augmedix offers AI-based solutions for the healthcare industry, allowing clinicians to spend more time on patient care. The company's solutions include remote medical documentation services and live clinical support services. Augmedix's above-average revenue growth makes it a promising stock with potential for long-term out-performance.

Augmedix: Using AI To Make Healthcare More Efficient

Committed to progressing scalable AI technologies, Augmedix's newest fully automated product is adaptable to serve acute and ambulatory care settings Committed to progressing scalable AI technologies, Augmedix's newest fully automated product is adaptable to serve acute and ambulatory care settings

Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile App

Clearwater Analytics Holdings

Lifeway Foods

Lifeway Foods (LWAY), Augmedix (AUGX) and Clearwater Analytics Holdings (CWAN) have been selected as the breakout stocks for today.

3 Best Breakout Stocks to Buy Now for Solid Returns

The council is comprised of distinguished leaders from various backgrounds and industries, and will provide guidance on matters related to Augmedix's use of generative AI The council is comprised of distinguished leaders from various backgrounds and industries, and will provide guidance on matters related to Augmedix's use of generative AI

News for Augmedix Stock (AUGX)